Research Will Help FDA Create Opioid Regulations
This article shows the importance of tackling critical health issues through groundbreaking research at the University of Kentucky, one of the main initiatives of the university's $2.1 billion comprehensive campaign, Kentucky Can: The 21st Century Campaign.
The United States Federal Drug Administration (FDA) has awarded a four-year $3.3 million contract to researchers at the University of Kentucky and University of North Carolina at Chapel Hill (UNC) to conduct studies to help the agency evaluate emerging technologies and provide information vital in making regulatory decisions.
Svetla Slavova, associate professor of biostatistics in the UK College of Public Health's Kentucky Injury Prevention and Research Center, will lead work that includes collaboration with the Kentucky All Schedule Prescription Electronic Reporting (KASPER) system, the Kentucky Office of Vital Statistics and the Office of the Chief Medical Examiner. Her team will continue to develop electronic linkage and connectivity of prescribing, mortality and toxicology data in Kentucky.
"The data will then be used to provide the FDA with improved monitoring of emerging medication risks," Slavova said. “The timeliness of data availability could revolutionize our concept of what can be learned about newly marketed drugs.”
Faculty at UK and UNC will conduct research to help the FDA better understand the use of opioid therapies and products designed to prevent abuse – and the impact of the products on use, overdose and fatalities.
The research studies also will increase the FDA’s knowledge of data systems and methods used in studying the impact of new medications as well as develop new data resources and methods that will be available as open-source research tools.
“We will develop a panoramic portrait of the opioid crisis, rather than a series of isolated data snapshots,” said Nabarun Dasgupta, senior research scientist at the UNC Injury Prevention Research Center and lead investigator on the project. “We’ll fundamentally improve the quality of information available to the FDA for regulatory decisions regarding opioids.”
The FDA also may add additional studies to extend the scope of the research in the second year of the project. These studies would engage scientists from RTI International and IBM Watson Health to explore further the themes of epidemiologic theory and methods and the lived experience of patients.
“The project unites UK and UNC – both powerhouses of research and practice in the areas of injury prevention and opioid addiction – in our common goal of turning the tide of the opioid crisis,” said Donna K. Arnett, Ph.D., dean of the UK College of Public Health. “The work undertaken by this impressive group of researchers will develop new tools to support FDA decision-making on opioid deterrence, with the potential to greatly improve population health nationwide.”
The multidisciplinary project team includes pain management physicians, pharmacists, ethnographers, people who use drugs, people living with chronic pain, statisticians, epidemiologists, state government officials and policy makers.
Other partnering institutions include DePaul University, Sawbuck Productions, Urban Survivors Union, the UK College of Pharmacy’s Institute for Pharmaceutical Outcomes and Policy and the University of Louisville.
Read more about UK's opioid research and the UK Center on Drug and Alcohol Research to see how UK researchers are tackling this local, national and international problem. Learn more about UK Research or support UK Research.
This article originally appeared in UK Now, written by Kristi Willett.